Michael John Tisdale

USPTO Granted Patents = 16 (Patent Applications = 22)

EPO Patents = 5 (Patent Applications = 1)

Average Co-Inventor Count = 2.5

ph-index = 6

Forward Citations = 231(Granted Patents)

Location History:

Claverdon, Warwickshire CV35 8LW, GB (2005)
Warwickshire, GB (2009 - 2012)
Birmingham, GB (2006 - 2014)
Claverdon, GB (1993 - 2019)

Company Filing History:

3 out of 61

Cancer Research Campaign Technology Limited

patents

3 out of 4,177

Abbott Laboratories Corporation

Takeda Chemical Industries, Inc.

8. 2 out of 832,680

Other

patents

Years Active: 1993-2019

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10172917 - [object Object] (2019-01-08),

2. 10077295 - Glycoproteins having lipid mobilizing properties and therapeutic uses thereof (2018-09-18),

3. 8778994 - Method of using beta-hydroxy-beta-methylbutyrate and fatty acids for treating disease-associated wasting (2014-07-15),

4. 8609725 - Method of using beta-hydroxy-beta-methylbutyrate for reducing tumor growth rate (2013-12-17),

5. 8329646 - Methods for the treatment of muscle loss (2012-12-11),

6. 8217077 - HMB uses thereof (2012-07-10),

7. 8207310 - Antibodies to proteolysis inducing factor (PIF) receptor and methods of use thereof (2012-06-26),

8. 7750181 - Antiproliferative agents (2010-07-06),

9. 7550429 - Glycoproteins having lipid mobilising properties and therapeutic applications thereof (2009-06-23),

10. 7049338 - Antiproliferative agents (2006-05-23),

11. 6890899 - Glycoproteins having lipid mobilizing properties and therapeutic applications thereof (2005-05-10),

12. 6881846 - Antiproliferative agents (2005-04-19),

13. 6133278 - Use of quinone and hydroquinone derivatives for the treatment of cachexia (2000-10-17),

14. 5457130 - Eicosapentaenoic acid used to treat cachexia (1995-10-10),

15. 5385740 - Biologically active material characterized by catabolic activity (1995-01-31),

Title: Michael John Tisdale: Innovator in Metabolic Disorder Treatments

Introduction

Michael John Tisdale is a notable inventor based in Warwickshire, GB. He has made significant contributions to the field of metabolic disorders, holding a total of 8 patents. His work focuses on innovative formulations and methods aimed at ameliorating symptoms associated with various metabolic conditions.

Latest Patents

Among his latest patents, Tisdale has developed formulations that provide targeted administration of Zn-α-glycoproteins or functional fragments to the esophagus. These inventions aim to address symptoms related to metabolic disorders such as hypoglycemia, obesity, and diabetes. Additionally, he has created glycoproteins with lipid mobilizing properties, which also target similar metabolic issues through the administration of various agents, including β-adrenergic receptor agonists and antagonists.

Career Highlights

Tisdale has had a distinguished career, working with reputable institutions such as Aston University and Epx Research Limited. His research has significantly advanced the understanding and treatment of metabolic disorders, showcasing his commitment to innovation in this critical area of health.

Collaborations

Throughout his career, Tisdale has collaborated with notable individuals, including Steven Russell and Washington Odur Ayuko. These partnerships have contributed to the development of his groundbreaking inventions.

Conclusion

Michael John Tisdale's work in the field of metabolic disorders exemplifies the impact of innovative thinking in healthcare. His patents and collaborations highlight his dedication to improving the lives of individuals affected by these conditions.

This text is generated by artificial intelligence and may not be accurate.